Joshua K. Sabari, MD

Oncologists discuss effective strategies for safely implementing combination therapies while managing adverse events to enhance patient outcomes.

Experts discuss the efficacy of amivantamab and lazertinib in treating EGFR mutations, highlighting improved outcomes and reduced CNS metastases.

The experts focus on clinical trial evidence supporting the use of combination therapies in EGFR-mutant mNSCLC. The panel reviews key data from the MARIPOSA and FLAURA trials, highlighting differences in patient populations, CNS imaging protocols, and reported outcomes. They emphasize that routine CNS surveillance allows for a more accurate assessment of intracranial progression-free survival and can inform optimal therapy selection. MARIPOSA trial data demonstrate that amivantamab plus lazertinib significantly improves intracranial progression-free survival compared to osimertinib monotherapy, effectively doubling outcomes in patients with baseline brain metastases. The discussion also addresses the importance of patient stratification based on risk factors, including high tumor burden, liver metastases, p53 mutations, and circulating tumor DNA levels, which may impact prognosis and response to therapy. The panel emphasizes that combination therapy is beneficial across populations, not limited to high-risk patients, and stresses the significance of first-line therapy selection in improving long-term outcomes. Safety profiles and tolerability are also introduced, noting the need for patient education and shared decision-making.

This opening segment establishes the program’s focus on EGFR-mutant mNSCLC, emphasizing the importance of identifying high-risk patient populations and discussing new combination therapies. The panel introduces the challenges in managing patients with CNS metastases, highlighting the need for effective systemic treatments that also demonstrate intracranial activity. Key agents, such as osimertinib and combinations with amivantamab and lazertinib, are briefly introduced, demonstrating their potential to improve progression-free survival and overall survival. The experts discuss the critical balance between treatment efficacy and patient quality of life, noting the importance of considering performance status and potential adverse events when selecting therapies. This segment also highlights that treatment decisions should be individualized, incorporating shared decision-making with patients. The speakers stress that CNS monitoring and early intervention are increasingly essential, and combination regimens are being explored as first-line strategies to maximize long-term benefit.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.

Panelists discuss how they implement prophylactic strategies for treatment-related adverse events in the MARIPOSA study and how they counsel patients about managing these effects.

Panelists discuss how the MARIPOSA study shows more patients in the amivantamab-lazertinib arm continued treatment compared to osimertinib, and many who progressed initiated subsequent therapy, primarily with carboplatin-pemetrexed.

Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib over osimertinib, the importance of managing adverse events, adherence to National Comprehensive Cancer Network guidelines, and the need for patient engagement in treatment discussions to address unmet needs.

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.

Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.

Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.

Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.

Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.

Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.

Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.

Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.

Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.

Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.

Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.

Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.

The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.

Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions.

Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.

Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.

The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.

A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.

Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, conclude their discussion with key takeaways on the evolving treatment of patients with NRG1 fusion–positive malignancies.

The expert panel discusses NRG1 fusions in pancreatic cancer and the potential role of zenocutuzumab as a therapeutic option.